Praxis sees encephalopathies asset relutrigine action date extended
· seekingalpha.com
FDA extends review of Praxis’ relutrigine for SCN2A/SCN8A epileptic encephalopathies to Dec. 27 after major amendment. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...